RxDoctor Payments Data

Sarah Snyder, NP

Family · Chattanooga, TNNPI 1689906968

Payments from drug & device makers

$4,255in general payments, 2019–2025

Across 250 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$390
  • Lilly USA, LLC$332
  • Pfizer$262
  • Boehringer Ingelheim$201
  • Astellas Pharma US Inc$185
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,255 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$82,946
Medicare patients
230
Services billed
3,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$116,595
TrulicityDulaglutide64$77,328
MounjaroTirzepatide49$51,874
JardianceEmpagliflozin51$48,461
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$27,809
EliquisApixaban30$25,837
FarxigaDapagliflozin Propanediol28$18,652
LinzessLinaclotide21$15,292
XareltoRivaroxaban16$12,207
Paxil CrParoxetine Hcl12$10,732
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$7,885
Combivent RespimatIpratropium/Albuterol Sulfate14$7,834
JanuviaSitagliptin Phosphate12$7,707
Rosuvastatin Calcium510$6,947
Spiriva RespimatTiotropium Bromide13$6,820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$332$129,202113 claims
Novo NordiskOzempic$1,256$116,595107 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$201$63,11678 claims
GSKTrelegy Ellipta$40$27,80933 claims
PfizerEliquis$262$25,83730 claims
AstraZenecaFarxiga$138$18,65228 claims
AbbVieLinzess$138$15,29221 claims
MerckJanuvia, Belsomra$95$12,86625 claims
Johnson & JohnsonXarelto$115$12,20716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →